Trial Profile
Phase 2 study of Cilcane in patients with relapsed refractory multiple myeloma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 May 2016 New trial record
- 25 May 2016 According to Iceni Pharmaceuticals media release, this study is expected to start in 2017.